BioSpace News Archive

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2022, and provides a corporate update.

BioNxt Solutions Inc. is pleased to report that it has signed a definitive technology transfer and patent assignment agreement to acquire certain technology and intellectual property assets and rights related to a novel solid oral drug dosage form coating and delivery technology.

MRM Health provided a business update on its different ongoing therapeutic programs and an outlook for 2023.

Patients aged 55 and younger were found to have worse pain, function and quality of life following total knee arthroplasty compared to patients 75 years and older, according to a study presented at the 2023 Annual Meeting of the American Academy of Orthopaedic Surgeons that looked at age-related differences in patient outcomes following TKA.

With an increase in total hip arthroplasty procedures being performed on younger patients, these patients have historically had poor long-term outcomes associated with implant failure.

Jeito Capital, the largest fully independent private equity firm dedicated to healthcare and biopharma in Europe, announced that it has co-led a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders.

Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association, announced that the European Medicines Agency has granted PRIME status to the gene therapy, GNT-0003, currently in clinical trials for Crigler-Najjar syndrome, a rare liver disease.

Theratechnologies Inc. announced receipt of a notification letter from The Nasdaq Stock Market LLC dated March 3, 2023, advising that the Company was not in compliance with Listing Rule 5550 as the bid price of the Company’s listed securities had closed at less than US$1.00 per share over the last 30 consecutive business days from January 19, 2023 to March 2, 2023.

Neuromod Devices Ltd. announced today that the US Food and Drug Administration (FDA) has granted De Novo approval to Lenire, the first bimodal neuromodulation device of its kind to be approved by the FDA for the treatment of tinnitus.

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, provided a business update and announced financial results for the year ended December 31, 2022.